Submit a manuscript Sign up for article alerts Contact us

RSS

Latest comments

Affiliation correction (Eloise Kok, 13 May 2011)

Dr. Teemu Luoto's affiliation should be corrected to Department of Neurosciences and Rehabilitation,
Tampere University Hospital, Biokatu 4, 33521 Tampere, Finland. read full comment

Comment on: Kok et al. Alzheimer's Research & Therapy, 3:12

Ginkgo biloba has a proven benefit (Siegfried Kasper, 07 December 2010)

Tian et al. arrive at a negative conclusion with regard to Ginkgo biloba for the treatment of Alzheimer's disease by relying on a Cochrane Review [1] and a study that did not really address the question they were trying to answer [2]. Unfortunately, the cited Cochrane review is flawed in that it lumps together studies using different Ginkgo products that can by no means be considered bioequivalent as well as studies in patients with different diseases or ailments (merely subjective memory complaints, mild cognitive decline, overt dementia). Obviously, it does not make sense to estimate a common effect size for 0.57 mg flavone glycosides and 0.97 mg ginkgolides per day in subjective cognitive complaints [3] and 58.8 mg flavone glycosides and 14.4 mg terpene lactones per day in dementia [4]... read full comment

Comment on: Tian et al. Alzheimer's Research & Therapy, 2:30

Traumatic brain injury and Alzheimer┬┐s disease (Rovshan Ismailov, 24 November 2010)

I agree with Dr. Gavett and colleagues that cohort studies with both detailed and accurate neuropathological assesement of patients diagnosed with head injury are needed. However, we also need more studies that would examine the mechanism of the association between traumatic brain injury and Alzheimer┬┐s... read full comment

Comment on: Gavett et al. Alzheimer's Research & Therapy, 2:18

Comment on Viewpoint Article - Con: Can neuropathology really confirm the exact diagnosis of dementia? (Kurt Jellinger, 28 June 2010)

Analysing 1,677 cases with antemortem diagnosis of dementia from the National Alzheimer's Coordination Registry, Nelson et al [1] recently commented on those cases that fall outside the National Institute on Aging and Reagan Institute (NIA-RI) recommendations. 82.4% fell into diagnostic "boxes" within the rubric of the consensus recommendations. Two specific categories were considered: (1) "tangle-intensive" cases with the highest density of neurofibrillary tangles but only moderate density of neuritic plaques (9.4% of the overall) were considered more likely to be designated as "high likelyhood" that dementia was due to AD, whereas (2) "plaque-intensive" patients with high density of amyloid plaques and intermediary severity tangles (6.0% of total) were typically designated as... read full comment

Comment on: Jellinger Alzheimer's Research & Therapy, 2:11